Wu Fei, Zhang Zhihong, Liu Shanshan
Department of Thyroid Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Department of General Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Front Oncol. 2025 Aug 27;15:1613697. doi: 10.3389/fonc.2025.1613697. eCollection 2025.
This study aimed to evaluate and compare the prognostic performance of Albumin-Bilirubin (ALBI), Platelet-Albumin-Bilirubin (PALBI), and Child-Pugh (CP) scores in predicting overall survival (OS) among patients with stage C hepatocellular carcinoma (HCC) with liver cirrhosis undergoing conventional transcatheter arterial chemoembolization (c-TACE).
We performed a retrospective cohort analysis of 151 cirrhotic patients with Barcelona Clinic Liver Cancer (BCLC) stage C HCC treated with c-TACE between 2017 and 2021. Pretreatment CP scores, ALBI, and PALBI were recorded, and their associations with OS were analyzed using Kaplan-Meier methods and receiver operating characteristic (ROC) curve analysis. Multivariate Cox models were used to determine independent survival predictors.
The median OS for the entire study cohort was 18.8 months (95% CI: 11.294-26.306 months). CP score, ALBI grade and PALBI grade were significantly correlated with OS (all P<0.05). Survival analysis revealed dose-dependent relationships: CP classes A and B demonstrated median OS of 22.9 vs 9.9 months (P<0.05), ALBI grades 1-3 corresponded to median OS of 25.7, 12.7, and 3.8 months respectively (P<0.05), PALBI grades 1-3 showed median OS of 25.7, 10.1, and 8.5 months (P<0.05). The area under the receiver operating characteristic curve (AUROC) values of CP score, ALBI grading, ALBI score, PALBI grading and PALBI score were 0.572, 0.550, 0.595, 0.619 and 0.637, respectively. Compared with the CP score and ALBI, PALBI showed a better predictive effect in patients with stage C hepatocellular carcinoma with cirrhosis treated with c-TACE. Multivariate analysis showed that CP grade, ALBI grade, PALBI grade, Portal vein invasion, and the number of c-TACE were independent predictors affecting the survival period of patients.
In cirrhotic patients with BCLC stage C HCC undergoing c-TACE, the PALBI scoring system emerged as a more reliable prognostic indicator than CP and ALBI assessments, showing enhanced discriminative capacity for survival outcomes.
本研究旨在评估和比较白蛋白-胆红素(ALBI)、血小板-白蛋白-胆红素(PALBI)和Child-Pugh(CP)评分在预测接受传统经动脉化疗栓塞术(c-TACE)的C期肝硬化肝细胞癌(HCC)患者总生存期(OS)方面的预后性能。
我们对2017年至2021年间接受c-TACE治疗的151例巴塞罗那临床肝癌(BCLC)C期肝硬化HCC患者进行了回顾性队列分析。记录治疗前的CP评分、ALBI和PALBI,并使用Kaplan-Meier方法和受试者工作特征(ROC)曲线分析来分析它们与OS的关联。使用多变量Cox模型确定独立的生存预测因素。
整个研究队列的中位OS为18.8个月(95%CI:11.294 - 26.306个月)。CP评分、ALBI分级和PALBI分级与OS显著相关(所有P<0.05)。生存分析显示出剂量依赖关系:CP A类和B类的中位OS分别为22.9个月和9.9个月(P<0.05),ALBI 1 - 3级对应的中位OS分别为25.7、12.7和3.8个月(P<0.05),PALBI 1 - 3级的中位OS分别为25.7、10.1和8.5个月(P<0.05)。CP评分、ALBI分级、ALBI评分、PALBI分级和PALBI评分的受试者工作特征曲线下面积(AUROC)值分别为0.572、0.550、0.595、0.619和0.637。与CP评分和ALBI相比,PALBI在接受c-TACE治疗的C期肝硬化肝细胞癌患者中显示出更好的预测效果。多变量分析表明,CP分级、ALBI分级、PALBI分级、门静脉侵犯和c-TACE次数是影响患者生存期的独立预测因素。
在接受c-TACE的BCLC C期肝硬化HCC患者中,PALBI评分系统是比CP和ALBI评估更可靠的预后指标,对生存结果具有更强的判别能力。